|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||16.73 - 17.63|
|52 Week Range||2.25 - 30.38|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 05, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.80|
WAYNE, Pa., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference. On Monday, September 13, 2021 at 7:00 a.m. ET, Dr. Neal Walker, the President and CEO of Aclaris, will virtually present a company over
Some Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders are probably rather concerned to see the share price fall...
Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.